A long term effect of recombinant interleukin 2 for HBeAg-positive chronic hepatitis.

概要

論文の詳細を見る
Recombinant interleukin 2 (rIL-2) was administered to 20 patients with HBeAg-positive chronic hepatitis. Ten patients were received 250 U per day of rIL-2 for 28 days intravenously and another ten patients were received 750 U per day of rIL-2 for 28 days intravenously.<BR>In patients treated with 250 U, HBeAg became negative in 2 cases (20%) and HBeAg became positive in 1 cases (10%) within 18 months. In patients treated with 750 U, HBeAg became negative in 6 cases (60%) and HBeAb became positive in 3 cases (30%) within 18 months. The younger patients with increased mean percent change from baseline level (100%) of s-GPT and decreased mean percent change from baseline level (100%) of DNA-P activity transiently during therapy showed higher incidence of HBeAg cleared. Fever, malaise, anorexia, headache, diarrhea, lymphocytosis and eosinophilia were observed transiently during therapy. But these symptoms did not necessitate discontinuation of therapy.<BR>These results suggest that rIL-2 therapy is effective for HBeAg-positive chronic hepatitis, and it is more effective for the younger patient received 750 U per day for 28 days and with significantly increased mean percent change from base line level (100%) of s-GPT and decreased mean percent change from baseline level (100%) of DNA-P activity transiently during therapy.
社団法人日本肝臓学会の論文